Fate Therapeutics, Inc. (FATE): Price and Financial Metrics

Fate Therapeutics, Inc. (FATE): $5.57

0.02 (+0.36%)

POWR Rating

Component Grades













Add FATE to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where FATE ranks best; there it ranks ahead of 80.78% of US stocks.
  • The strongest trend for FATE is in Stability, which has been heading down over the past 177 days.
  • FATE ranks lowest in Stability; there it ranks in the 1st percentile.

FATE Stock Summary

  • Of note is the ratio of FATE THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 8.73% of US stocks have a lower such ratio.
  • As for revenue growth, note that FATE's revenue has grown 72.44% over the past 12 months; that beats the revenue growth of 89.79% of US companies in our set.
  • The volatility of FATE THERAPEUTICS INC's share price is greater than that of 94.33% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to FATE THERAPEUTICS INC, a group of peers worth examining would be ARVN, DNLI, ATRA, XNCR, and RNA.
  • Visit FATE's SEC page to see the company's official filings. To visit the company's web site, go to www.fatetherapeutics.com.

FATE Valuation Summary

  • FATE's price/earnings ratio is -1.9; this is 108.19% lower than that of the median Healthcare stock.
  • Over the past 115 months, FATE's price/earnings ratio has gone up 5.4.

Below are key valuation metrics over time for FATE.

Stock Date P/S P/B P/E EV/EBIT
FATE 2023-03-24 5.5 1.1 -1.9 -2.0
FATE 2023-03-23 5.3 1.1 -1.8 -1.9
FATE 2023-03-22 5.2 1.0 -1.8 -1.9
FATE 2023-03-21 5.5 1.1 -1.9 -2.0
FATE 2023-03-20 5.7 1.1 -1.9 -2.1
FATE 2023-03-17 5.6 1.1 -1.9 -2.0

FATE Growth Metrics

    The 2 year price growth rate now stands at 1.56%.
  • Its 5 year cash and equivalents growth rate is now at 142.06%.
  • Its 5 year net cashflow from operations growth rate is now at -207.58%.
Over the past 49 months, FATE's revenue has gone up $64,907,000.

The table below shows FATE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 69.013 -243.112 -293.979
2022-06-30 68.257 -221.44 -253.724
2022-03-31 63.12 -200.387 -232.752
2021-12-31 55.846 -162.87 -212.151
2021-09-30 54.675 -113.241 -196.641
2021-06-30 48.008 -110.599 -212.017

FATE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FATE has a Quality Grade of D, ranking ahead of 19.68% of graded US stocks.
  • FATE's asset turnover comes in at 0.058 -- ranking 313th of 680 Pharmaceutical Products stocks.
  • RMTI, SYBX, and PTE are the stocks whose asset turnover ratios are most correlated with FATE.

The table below shows FATE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.058 1 -0.324
2021-03-31 0.054 1 -0.384
2020-12-31 0.057 1 -0.550
2020-09-30 0.039 1 -0.586
2020-06-30 0.033 1 -0.572
2020-03-31 0.036 1 -0.625

FATE Price Target

For more insight on analysts targets of FATE, see our FATE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $109.83 Average Broker Recommendation 1.47 (Moderate Buy)

FATE Stock Price Chart Interactive Chart >

Price chart for FATE

FATE Price/Volume Stats

Current price $5.57 52-week high $43.12
Prev. close $5.55 52-week low $4.02
Day low $5.53 Volume 76,293
Day high $5.66 Avg. volume 3,840,939
50-day MA $5.86 Dividend yield N/A
200-day MA $18.39 Market Cap 546.76M

Fate Therapeutics, Inc. (FATE) Company Bio

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.

FATE Latest News Stream

Event/Time News Detail
Loading, please wait...

FATE Latest Social Stream

Loading social stream, please wait...

View Full FATE Social Stream

Latest FATE News From Around the Web

Below are the latest news stories about FATE THERAPEUTICS INC that investors may wish to consider to help them evaluate FATE as an investment opportunity.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Yahoo | March 27, 2023

Fate Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 43rd Annual TD Cowen Health Care Conference on Wednesday, March

Yahoo | March 3, 2023

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors section of Fate’s website at fatetherapeutics.com. As a reminder, today’s call […]

Yahoo | March 3, 2023

Fate Therapeutics Full Year 2022 Earnings: Beats Expectations

Fate Therapeutics ( NASDAQ:FATE ) Full Year 2022 Results Key Financial Results Revenue: US$96.3m (up 72% from FY 2021...

Yahoo | March 2, 2023

FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.

Yahoo | March 1, 2023

Read More 'FATE' Stories Here

FATE Price Returns

1-mo -8.99%
3-mo -44.80%
6-mo -75.15%
1-year -86.03%
3-year -75.95%
5-year -42.93%
YTD -44.80%
2022 -82.76%
2021 -35.65%
2020 364.64%
2019 52.53%
2018 109.98%

Continue Researching FATE

Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:

Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0938 seconds.